Literature DB >> 11860452

Platelet-derived growth factor (PDGF) in human acute myelogenous leukemia: PDGF receptor expression, endogenous PDGF release and responsiveness to exogenous PDGF isoforms by in vitro cultured acute myelogenous leukemia blasts.

B Foss1, E Ulvestad, Ø Bruserud.   

Abstract

We investigated effects of Platelet-derived growth factor (PDGF) and Platelet factor 4 (PF-4) on the functional characteristics of native, human acute myelogenous leukemia (AML) blasts. AML blast expression of the PDGF-receptor alpha-chain was detected for a subset of patients (45%), whereas PDGF-receptor beta-chain expression was detected for most patients (90%). Constitutive AML blast release of the PDGF-AB isoform (the major form also derived from normal platelets) was detected for 43% of patients, whereas PDGF-BB release was not detected for any patient. The PDGF isoforms AA, AB and BB had dose-dependent and divergent effects on spontaneous and cytokine-dependent AML blast proliferation, whereas for constitutive cytokine secretion (IL-1beta, IL-6, TNF-alpha) inhibitory effects were rare and all three isoforms usually had no effect or enhanced the constitutive secretion. The PDGF effects were caused by a direct effect on the AML blasts and were not dependent on the presence of serum. The PDGF effects could also be detected after in vitro culture of AML cells in the presence of IL-4+ granulocyte-macrophage colony stimulating factor. PF-4 had divergent effects on proliferation and cytokine secretion by native AML blasts. Our results suggest that exogenous (e.g. platelet-secreted) PDGF and PF-4 can function as regulators of leukemic hematopoiesis and possibly also modulate the function of residual AML cells in peripheral blood stem cell grafts. On the other hand, endogenous release of PDGF-AB by native blasts may modulate the function of normal cells in the bone marrow microenvironment (e.g. bone marrow stromal cells).

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11860452     DOI: 10.1034/j.1600-0609.2001.0430a.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  5 in total

1.  A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia.

Authors:  Christoph Schliemann; Joachim Gerss; Stefanie Wiebe; Jan-Henrik Mikesch; Nicola Knoblauch; Tim Sauer; Linus Angenendt; Tobias Kewitz; Marc Urban; Trude Butterfass-Bahloul; Sabine Edemir; Kerstin Vehring; Carsten Müller-Tidow; Wolfgang E Berdel; Utz Krug
Journal:  PLoS One       Date:  2016-10-07       Impact factor: 3.240

2.  MDM2- and FLT3-inhibitors in the treatment of FLT3-ITD acute myeloid leukemia, specificity and efficacy of NVP-HDM201 and midostaurin.

Authors:  Katja Seipel; Miguel A T Marques; Corinne Sidler; Beatrice U Mueller; Thomas Pabst
Journal:  Haematologica       Date:  2018-07-05       Impact factor: 9.941

Review 3.  Allogeneic transplant for FLT3-ITD mutated AML: a focus on FLT3 inhibitors before, during, and after transplant.

Authors:  Abdul Hamid Bazarbachi; Rama Al Hamed; Florent Malard; Mohamad Mohty; Ali Bazarbachi
Journal:  Ther Adv Hematol       Date:  2019-11-01

4.  The novel tyrosine kinase inhibitor AKN-028 has significant antileukemic activity in cell lines and primary cultures of acute myeloid leukemia.

Authors:  A Eriksson; M Hermanson; M Wickström; E Lindhagen; C Ekholm; A Jenmalm Jensen; A Löthgren; F Lehmann; R Larsson; V Parrow; M Höglund
Journal:  Blood Cancer J       Date:  2012-08-03       Impact factor: 11.037

5.  An aberrantly sustained emergency granulopoiesis response accelerates postchemotherapy relapse in MLL1-rearranged acute myeloid leukemia in mice.

Authors:  Hao Wang; Chirag A Shah; Liping Hu; Weiqi Huang; Leonidas C Platanias; Elizabeth A Eklund
Journal:  J Biol Chem       Date:  2020-05-28       Impact factor: 5.157

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.